Avalo Therapeutics, Inc. (AVTX)
19.36
+0.41
(+2.16%)
USD |
NASDAQ |
Sep 02, 10:41
Avalo Therapeutics Research and Development Expense (Annual) : 50.08M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 50.08M |
| December 31, 2024 | 24.44M |
| December 31, 2023 | 13.78M |
| December 31, 2022 | 31.31M |
| December 31, 2021 | 59.84M |
| December 31, 2020 | 32.19M |
| December 31, 2019 | 11.76M |
| Date | Value |
|---|---|
| December 31, 2018 | 5.787M |
| December 31, 2017 | 4.373M |
| December 31, 2016 | 10.15M |
| December 31, 2015 | 6.587M |
| December 31, 2014 | 12.24M |
| December 31, 2013 | 8.914M |
| December 31, 2012 | 8.477M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Incyte Corp. | 1.984B |
| AbbVie, Inc. | 8.249B |
| Rezolute, Inc. | 61.53M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |